Physicochemical Characterization and Solubility Analysis of Thalidomide and Its N-Alkyl Analogs by Goosen, Colleen et al.
Physicochemical Characterization and
Solubility Analysis of Thalidomide
and Its N-Alkyl Analogs
Colleen Goosen,1,3,6 Timothy J. Laing,4
Jeanetta du Plessis,1 Theunis C. Goosen,2,5 and
Gordon L. Flynn3
Received April 10, 2001; accepted September 27, 2001
Purpose. The present study was primarily aimed at exploring the
feasibility of improving percutaneous delivery via chemical manipu-
lation of the thalidomide molecule to form analogs with improved
physicochemical properties. N-Alkyl analogs were synthesized with
the belief that these would be suitably hydrophobic and far less crys-
talline than the reference compound. This article presents their phys-
icochemical properties.
Methods. Thalidomide and three of its N-alkyl analogs were synthe-
sized. Identification and levels of purity (>96%) were assured
through element analysis, fast atom-bombardment mass spectrom-
etry, nuclear magnetic resonance spectroscopy, and high-
performance liquid chromatography. N-Octanol/water partition co-
efficients were determined at pH 6.4. Solubilities in water and a series
of n-alkanols were obtained. Best-fit solubility parameters were de-
termined from the solubilities of the respective compounds in Lon-
don solvents and were also calculated from respective hexane solu-
bilities, melting points and heats of fusion.
Results. Methylation of the thalidomide molecule at its acidic nitro-
gen led to an aqueous solubility about 6-fold higher than thalidomide
but, because the alkyl chain length was further extended from methyl
to pentyl, aqueous solubilities decreased essentially exponentially.
The destabilization of the crystalline structure with increasing alkyl
chain length led to an increased solubility in nonpolar media. The log
partition coefficient increased linearly with increasing alkyl chain
length and the solubility parameters declined systematically through
this series. By adding a methyl group to the thalidomide structure, the
melting point dropped by more than 100°C. Adding to the alkyl chain
length led to further, more modest decreases. Heats of fusion de-
creased dramatically upon thalidomide’s alkylation as well.
Conclusion. Alkylation of the thalidomide molecule resulted in com-
pounds with physicochemical properties that appear to be markedly
better suited for percutaneous delivery.
KEY WORDS: thalidomide; N-alkyl analogs; solubility parameter;
lipophilicity; solubility.
INTRODUCTION
Synthesized in Germany in 1954, thalidomide was intro-
duced into the pharmaceutical market in 1956 as a sedative
and hypnotic drug. Soon after, it came into use as a tranquil-
izer and anti-emetic for pregnant women. Tragically, it was
soon found to be teratogenic and had to be withdrawn from
the market. However, it remained available in certain coun-
tries for research purposes. In 1964, Sheskin discovered that
thalidomide was beneficial in the treatment of erythema no-
dosum leprosum (1). Clinical and immunologic similarities
between the leprotic reaction of erythema nodosum leprosum
and diffuse connective tissue diseases, particularly rheuma-
toid arthritis (RA), have been observed (2). Gutiérrez–
Rodríguez (3) proved that the systemic administration of tha-
lidomide to patients with RA results in rapid clinical improve-
ment, although unacceptable side effects were observed. The
action has been linked to the ability of thalidomide to sup-
press the synthesis of tumor necrosis factor alpha (TNF). An
alternative means of delivering thalidomide to minimize some
of its adverse effects would be desirable. We reasoned that
percutaneous delivery might allow the drug to be delivered
into the joints and other affected areas of the extremities
without raising systemic levels to a worrisome point.
For a drug to be taken seriously as a candidate for per-
cutaneous delivery, it must have suitable physicochemical
properties, particularly with respect to its absolute and rela-
tive solubilities and related partitioning tendencies (4,5).
Based on thalidomide’s physicochemical properties (high
melting point and low lipophilicity), it appeared unlikely that
it would be delivered percutaneously in amounts required for
arresting the symptoms of RA. Given the potential clinical
efficacy of TNF inhibitors such as thalidomide in a wide
range of immunologic disorders (1,6–8), especially RA (9), it
seemed worthwhile to investigate what changes in thalido-
mide’s structure might produce an active compound suitable
for skin transport. It is for this reason that we have embraced
the idea of synthesizing N-alkyl analogs of thalidomide (Fig.
1), which should exhibit decreased crystallinity and increased
lipophilicity. Therefore, the solubilities and lipophilicities of
thalidomide and several N-alkyl analogs were determined.
MATERIALS AND METHODS
For the synthesis of thalidomide and its N-alkyl analogs,
N-phthaloyl-DL-glutamic anhydride and urea were obtained
from Aldrich (Milwaukee, WI) and methylamine, propyl-
amine, and n-amylamine were obtained from Sigma Chemical
Co. (St. Louis, MO). For solubility studies, reagent-grade or-
ganic solvents (Aldrich, Milwaukee, WI) were used as re-
ceived. High-performance liquid chromatography (HPLC)
grade acetonitrile and methanol (Fisher Scientific, Pittsburgh,
PA) were used for the chomatography procedure and to di-
lute samples in preparation for HPLC analysis, respectively.
Thalidomide and its analogs were synthesized according to
literature methods (10,11) but with modification of the pub-
lished purification procedures. Identification and levels of pu-
rity (>96%) were assured through element analysis, fast
atom-bombardment mass spectrometry, nuclear magnetic
resonance (1H-NMR and 13C-NMR) spectroscopy, HPLC,
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and by the sharpness of melting points. Fast atom-bombard-
ment mass spectra were recorded using xenon13 as the bom-
bardment gas (8 kV, 1 mA). The mass spectrometer was op-
erated at 6 kV, and the magnetic analyser scanned at a rate of
5 s per decade over a mass range of 50–500 Da. These oper-
ating parameters applied to both positive- and negative-ion
analysis. Samples were directly dissolved in the matrix and
ionized on stainless steel targets at room temperature. 1H-
and 13C-NMR spectra were performed at 30°C on a Varian
Gemini-300 spectrometer operating at 400.08 and 75.46 MHz,
respectively, using DMSO as a reference.
Synthesis Method
Thalidomide (Racemic Mixture)
One mol of N-phthaloyl-DL-glutamic anhydride was
melted with 2 mol of urea in an oil bath at 170–180°C for 45
min. After cooling, the crude thalidomide was dissolved in 60
mL of ethanol (95%), heated to 60°C, and cooled. The crys-
tallization was repeated three more times. Thalidomide was
obtained as an almost white powder, with a melting point of
275°C and a yield of 70–75%. Anal (C13H10N2O4) calc. C
60.52% N 10.86% H 3.91%, found C 60.48% N 10.96% H
3.97%. 1H-NMR (DMSO-d6) : 7.89 (m, 4H, aromatic pro-
tons), 5.16 (1H, dd, J  5.4, 12.8, H-1), 2.08, 2.57, and 2.90
(3×m, 2×CH2 of piperidinedione ring), 11.00 (1H, brs, NH);
13C-NMR (DMSO-d6) : 172.92, 170.00 and 167.33 (4×CO),
134.96, 131.35 and 123.49 (aromatic carbon atoms), 49.02 (C-
1), 30.91 (C-5), 21.95 (C-6), m/z 259 (M+ + 1, 50), 154 (100),
136 (75), 120 (16), and 107 (27).
N-Methyl Thalidomide (Racemic Mixture)
One mol of N-phthaloyl-DL-glutamic anhydride and 1.2
mol of a 2 M methylamine solution in methyl alcohol were
heated in an oil bath at 200°C for 8 h. After cooling, the crude
imide was purified by recrystallization from 95% ethanol. The
crude imide was dissolved in ethanol, heated to 60°C and then
cooled at 4°C. This recrystallization process was repeated 5
times. De and Pal (11) purified N-methyl thalidomide by sub-
limation and a melting point of 131–133°C was reported. In
this study, N-methyl thalidomide was purified by recrystalli-
zation from 95% ethanol and a melting point of 159°C was
obtained and yields of 60–70%. According to HPLC, element
analysis and the sharpness of the melting point, a high purity
(98%) was obtained for N-methyl thalidomide. Anal
(C14H12N2O4) calc. C 61.82% N 10.30% H 4.45%, found C
61.82% N 10.26 H 4.50%. 1H-NMR (DMSO-d6) : 7.85 (m,
4H, aromatic protons), 5.18 (1H, dd, J  5.4, 12.8, H-1), 2.95,
2.75, 2.55, and 2.05 (4×m, 2×CH2 of piperidinedione ring),
3.05 (3H, s, CH3);
13C-NMR (DMSO-d6) : 172.48, 170.48,
and 168.03 (4×CO), 135.81, 132.11, and 124.36 (aromatic car-
bon atoms), 50.44 (C-1), 31.97 (C-5), 22.05 (C-6), 27.50
(CH3); m/z 272 (M
+, 53), 186 (8), 162 (100), 154 (41), 137 (40),
and 107 (15).
N-Propyl Thalidomide (Racemic Mixture)
One mol of N-phthaloyl-DL-glutamic anhydride and 1.2
mol of 99% propylamine were heated in an oil bath at 200°C
for 8 h. After cooling, the crude imide was purified by recrys-
tallization from ethanol (95%). The crude imide was dis-
solved in ethanol, heated to 60°C and then cooled at −20°C.
This recrystallization process was repeated five times. The
final product was an off-white powder with a melting point of
136°C and yields of 50–60%. A 66–68°C melting point was
previously reported for the compound by De and Pal (11).
Anal (C16H16N2O4) calc. C 64.06% N 9.34% H 5.38, found C
64.09% N 9.31% H 5.56%. 1H-NMR (DMSO-d6) : 7.92 (m,
4H, aromatic protons), 5.25 (1H, dd, J  5.4, 12.8, H-1), 3.63
(m, 2H, N-CH2), 2.96, 2.78, 2.54 and 2.09 (4×m, 2×CH2 of
piperidinedione ring), 1.45 (m, 2H, CH2), 0.83 (3H, t, CH3);
13C-NMR (DMSO-d6) : 172.46, 170.28, 168.02 (4×CO),
135.79, 132.11, 124.33 (aromatic carbon atoms), 50.47 (C-1),
31.99 (C-5), 22.19 (C-6), 41.88 and 22.18 (2×CH2 of propyl
group), 11.97 (CH3); m/z 300 (M
+, 100), 273 (6), 186 (38), 154
(23), 137 (28), and 126 (22).
N-Pentyl Thalidomide (Racemic Mixture)
One mol of N-phthaloyl-DL-glutamic anhydride was
heated with 1.2 mol of N-amylamine (99%) in an oil bath at
200°C for 8 h. After unsuccessful attempts at distillation, the
crude N-pentyl thalidomide was purified by silica gel column
chomatography (diethyl either:hexane) using a stepwise gra-
dient (10:90, 20:80, 30:70, 40:60; and 45:55). The volume of
each mobile phase used was two times the column volume
and N-pentyl thalidomide was collected during the 45% di-
ethyl ether mobile phase elution. It was dried in vacuo and
recrystallized once from diethyl ether, yielding white crystals
of N-pentyl thalidomide and yields of 40–60%. According to
the literature (11), N-pentyl thalidomide can be purified by
distillation in vacuo and a 19–21°C melting point was re-
ported. A melting point of 105°C was determined for N-
pentyl thalidomide. Anal (C18N20N2O4) calc. C 65.91% N
8.54% H 6.15%, found C 65.55% N 8.45% H 6.08%. 1H-
NMR (DMSO-d6) : 7.90 (m, 4H, aromatic protons), 5.22
(1H, dd, J  5.4, 12.8, H-1), 3.63 (m, 2H, N-CH2), 2.98, 2.74,
2.50, and 2.07 (4×m, 2×CH2 of piperidinedione ring), 1.40 and
1.22 (2×m, 2H and 4H, 3×CH2), 0.83 (3H, t, CH3);
13C-NMR
(DMSO-d6) : 171.67, 169.47 and 167.30 (4×CO), 134.90,
131.35 and 123.51 (aromatic carbon atoms), 49.61 (C-1),
39.42, 28.27, 26.87, and 21.24 (4×CH2 of pentyl chain), 13.64
(CH3), 31.09 (C-5) and 21.66 (C-6); m/z 328 (M
+, 100), 301
(6), 186 (44), 173 (5), 154 (16), and 130 (5).
Fig. 1. Structures of thalidomide and its N-alkyl analogs.
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Chromatographic Procedure
The HPLC system consisted of a Beckman 114M solvent
delivery system and a Spectraflow 783 variable wavelength
ultraviolet detector, operated at 220 nm and a flow rate of 1.2
mL/min. A Perkin–Elmer ISS-100 autoinjector was used to
inject samples (20 L) onto a Spheri-5 (RP-8, 5 m, 220 × 4.6
mm) column (Alltech Associates, Inc., Deerfield, IL) and a
NewGuard precolumn (RP-18, 7 , 15 × 3 mm) insert was
used. The mobile phase comprised of acetonitrile:water (25%
acetonitrile for thalidomide and N-methyl thalidomide and
35% and 45% for N-propyl and N-pentyl thalidomide, respec-
tively). The pH was adjusted to 2 with ortho-phosphoric acid
(Fluka Chemical Co., Ronkonkoma, NY). Calibration curves
established that excellent linearity existed over the entire con-
centration range from 0.01 g/mL to 10 g/mL.
Solubility Determination
The 25°C solubilities of thalidomide and its N-alkyl ana-
logs in hexane, cyclohexane, carbon tetrachloride, toluene,
benzene and phosphate buffer (pH 6.4) and the 32°C solu-
bilities in phosphate buffer (pH 6.4) and an extended series of
n-alkanols were obtained by equilibrating excess amounts of
each of the compounds with these solvents. Samples were
filtered (PTFE filter media with Polypropylene housing, 0.45-
m pore size, Whatman Inc., Haverhill, MA) and measured
with respect to volume. The solvent from each individual
sample was then evaporated and reconstructed in an appro-
priate amount of methanol or directly diluted with methanol
and assayed by HPLC.
Differential Thermal Analysis
The heat (Hf) and entropy (Sf) of fusion of thalido-
mide and its N-alkyl analogs were determined with a Perkin–
Elmer DSC7 Differential Scanning Calorimeter (DSC). Heat-
ing curves were recorded at 10°C/min. All tracings were re-
peated four times. There were no appreciable differences
(±4%) in the thermograms for any compound from run to
run.
Melting Point Determination
The melting points of thalidomide and its N-alkyl analogs
were determined by two methods: (1) differential thermal
analysis (as described above) and (2) controlled-heating ther-
mal microscopy (Mettler Hot Stage with FPS Temperature
Regulator and a Zeiss Standard Microscope). The heating
rate for both methods was 10°C/min.
Partition Coefficient Determination
Solutions of each compound in this study were prepared
with phosphate buffer (pH 6.4)-saturated octanol and trans-
ferred to assay tubes containing equal volumes of phosphate
buffer. These mixtures were agitated for 2 h and after cen-
trifugation at 2000 g for 10 min, the n-octanol and buffer
phases were analyzed by HPLC. Partition coefficients (Koct)
were calculated as the ratio of drug concentration in the n-
octanol phase to that in the buffer phase.
RESULTS
Table I summarizes the physicochemical properties of
thalidomide and its N-alkyl analogs. Enthalpies of fusion,
Hf, and entropies of fusion, Sf, are also shown in Table I.
Thalidomide, N-propyl thalidomide and N-pentyl thalido-
mide exhibited only one thermal transition each. The endo-
therms at 275, 136, and 105°C, correspond to the melting of
these crystals, respectively. N-Methyl thalidomide showed a
major endotherm at 159°C and a small endotherm at 165°C.









(g/mol) 258 272 300 328
Crystalline density
(g/mL) 1.48 1.43 1.35 1.28
Molar volume, V2
(mL/mol) 174 191 223 255
Melting Temperature,
Tf(°C) ± SD 275 ± 0.11 159 ± 0.11 136 ± 0.90 105 ± 0.26
Heat of fusion, Hf
(kcal/mol) ± SD 8.61 ± 0.27 4.33 ± 0.06 6.52 ± 0.25 5.73 ± 0.08
Entropy of fusion, Sf
(cal/mol/K) 15.71 10.02 15.94 15.16
Activity of solid phase
as2, Cp  0* 1.29 × 10
−3 1.03 × 10−1 5.18 × 10−2 1.29 × 10−1
Activity of solid phase
as2, Cp  Sp* 8.07 × 10
−3 1.54 × 10−1 7.89 × 10−2 1.64 × 10−1
Solubility parameter, 2
(cal/cm3)1/2, Cp  0 13.2 12.2 11.4 11.2
Solubility parameter, 2
(cal/cm3)1/2, Cp  Sp 13.7 12.3 11.5 11.2
Ln X2, ideal (Cp  0) −6.65 −2.27 −2.96 −2.05
Ln X2, ideal (Cp  Sp) −4.82 −1.87 −2.54 −1.81
* Ideal activity of solid phase, as2 estimated from Eq. 1 (15) with one or the other assumption.
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The endotherm at 159°C corresponds to the melting point of
N-methyl thalidomide, suggesting that the small subsequent
energy absorption involved relaxation of structure in the liq-
uid state. Melted samples of all the compounds, assayed by
HPLC showed only trace amounts (less than 0.5%) of decom-
position, and it was assumed that the endotherms primarily
represent energy consumed on melting.
A physical parameter that is necessary for solubility
analysis is the molar volume of liquid solute. The molar vol-
ume, V2, of thalidomide was determined from its molecular
weight divided by its crystalline density (12). Because the
crystalline densities of the N-alkyl analogs were not known,
their molar volumes were estimated, starting with thalido-
mide’s true molar volume, by summation and subtraction of
functional-group molar volumes that distinguish the indi-
vidual compounds from thalidomide (13). The essentials of
estimation of the molar volumes for the N-alkyl analogs are
presented in Table II.
The aqueous and hexane solubilities of thalidomide and
its N-alkyl analogs are listed in Table III along with their
octanol/water partition coefficients (Koct). The solubilities of
these compounds in a series of n-alkanols are summarized in
Table IV on a molar scale. It can be seen that for every solute
the molar solubilities across the homologous series of solvents
decrease systematically with increasing alkanol chain length.
The hexane solubilities of the compounds can be seen in
Table III. The assumption that the volume fraction of hexane
in the saturated solutions (1), is unity, was made (14). Using
this surmise, the solubility parameters for all the solutes were
calculated according to Eq. 3 (15) and the assumption that
Cp  0 or Cp  Sf . The mol fraction solubilities (ln X)
of thalidomide and its N-alkyl analogs in several organic sol-
vents at 25°C are listed in Table V, as well as the values of the
solubility parameters of the solvents. To show the extent to
which thalidomide’s and the analogs’ solubility behavior
might conform to regular solution behavior, the regular solu-
tion solubility parabolas for all four compounds were calcu-
lated according to Roy and Flynn (15) (Eq. 3) (with the as-
sumption, Cp  Sf and Cp  0) where in each case the
solutions are considered ideal (Fig. 2 A–D).
DISCUSSION
Structures of Thalidomide and Its N-Alkyl Analogs
Thalidomide
In the 1H-NMR spectrum of thalidomide, the four pro-
tons of the aromatic ring resonate as a symmetrical multiplet
at  7.89. The signal from H-1 appears as a doublet of dou-
blets (J 5.4 and 12.8) at  5.16. The remaining four protons on
the piperidinedione ring appear as three sets of multiplets at
 2.08, 2.57, and 2.90. The amine proton resonates as a broad
singlet at ca.  11.00. In the 13C-NMR spectrum of thalido-
mide three signals at  172.92, 170.00, and 167.33 attributable
to the four carbonyl carbon atoms and three signals at 134.96,
131.35, and 123.49 attributable to the six aromatic carbon
atoms are clearly discernable. The three remaining carbon
atoms of the piperidinedione ring resonate at 49.02 (C-1),
30.91 (C-5), and 21.95 (C-6), respectively.
N-Methyl Thalidomide
The 1H-NMR spectrum of N-methyl thalidomide is iden-
tical to that of thalidomide except for the signal from the
methyl group at  3.05 in the 1H-NMR spectrum and at 
27.50 in the 13C-NMR spectrum.
N-Propyl Thalidomide
The 1H-NMR spectrum of the N-propyl analog shows in
addition to the signals of the thalidomide nucleus a multiplet
at each of  3.63 and 1.45 due to the methylene protons and
a triplet at  0.83 due to the methyl group of the propyl
moiety. In addition to the signals of the thalidomide nucleus
the 13C-NMR spectrum of the N-propyl analog shows signals
at  41.88 and 21.53 due to the methylene carbon atoms and
11.97 arising from the methyl group of the propyl moiety.
N-Pentyl Thalidomide
The 1H-NMR spectrum of the N-pentyl analog shows in
addition to the signals of the thalidomide nucleus a multiplet
at  3.63 and 1.40 for the terminal methylene groups of the
pentyl moiety whereas the signal from the two central meth-
ylene groups appears as a multiplet at  1.22 and the methyl
group resonate as a triplet at  0.83. In addition to the signals
from the thalidomide nucleus the 13C-NMR spectrum of the
N-pentyl analog shows signals due to methylene carbon atoms
at  39.42, 28.27, 26.87, and 21.24 whereas the methyl group
resonates at  13.64.
Physicochemical Properties
N-Alkylation of the glutarimide ring in the thalidomide
molecule replaces the imido hydrogen atom, which is respon-
sible for strong hydrogen and dipolar bonding within the crys-
talline state. The melting points for the N-alkyl analogs in this
series are all at least 100°C lower than thalidomide’s melting













Thalidomide 174.33 174.33 174.33 174.33
H 3.1 −3.1 −3.1 −3.1
CH2 16.2 — +32.4 +64.8
CH3 19.3 +19.3 +19.3 +19.3
Estimated molar volume (mL/mol) 191 223 255
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point, illustrating the remarkable impact of eliminating the
acidic imido hydrogen atom of the thalidomide molecule.
Table I contains estimates of the thermodynamic activi-
ties of thalidomide and its N-alkyl analogs at 25°C. These
were obtained using Equation 1 according to Roy and Flynn
(15) in conjunction with the experimental values for Hf and
Tf . These values also represent the mol fractional ideal solu-
bilities. It can be seen that the inherent thermodynamic ac-
tivity increases dramatically when the thalidomide structure is
alkylated. However, there is no simple pattern to the thermo-
dynamic activities of the analogs as a result of extending the
alkyl chain. Although it is inappropriate to directly relate the
thermodynamic activity of one compound to that of another,
as there is no provision in classical thermodynamics for doing
so, it is still clear from these data that a high level of crystal-
linity is associated with low activity and vice versa. It must
always be kept in mind that it is the thermodynamic activity of
a drug in a solution that establishes its maximum practical
driving force for its escape from the solution.
At 52 g/mL (Table III), the 25°C aqueous solubility of
thalidomide is exceptionally low. Its low solubility in water is
undoubtedly due in part to the exceptionally high level of
crystallinity reflected in its high melting point and enthalpy of
fusion. There may be other factors here that also have bearing
on the value. By way of contrast, the aqueous solubility of
N-methyl thalidomide, 276 g/mL, is quite high. The loss of
the imido hydrogen’s ability to H-bond with water is more
than compensated for by the reduced crystallinity of the com-
pound. Based on this general behavior of amines (17,18), one
can also speculate that the change in structure also slightly
increases the strength of the nitrogen atom as an H-bond
receptor. In the instances of the N-propyl and N-pentyl ana-
logs, further reductions in compound crystallinity are insuffi-
cient to overcome the impact of making the compounds in-
crementally more hydrophobic and the aqueous solubility
drops dramatically.
N-alkylation of the glutarimide ring in the thalidomide
molecule results in compounds that are more lipophilic. This
is evident from the systematically declining solubility param-
eters through the series (Table I) but is even better demon-
strated in the octanol/water partition coefficients (Table III).
Table IV summarized a display of the solubilities of tha-
lidomide and analogs in the simple straight chain alkanols.
The impact of extending the alkyl chain length is greatest on
thalidomide, which exhibits a 28-fold decrement in solubility
from methanol to dodecanol. As might be expected, the im-
pact declines as the lipophilicity of the compounds is in-
creased. Thus, as the compounds are made increasingly hy-
drophobic, the impact of increasing the hydrophobicity of the
solvents is lessened.
The demonstrated loss of capacity of the alkanols to dis-
solve each of the compounds is relatively important. There
are two identifiable “forces” acting here. The alkanol solvents
are becoming more hydrophobic as their chain lengths are
lengthened. The increased hydrophobicity in principle can
have a positive or negative effect on solubility depending on
whether the direction makes the solvents more like or less
like the respective solutes (whether the cohesive energy den-
sities of the solvents are moving towards or away from the
cohesive energy densities of the supercooled liquid form of
the respective solutes). The second “force” derives from the
fact that, as the alkyl chain length of the alkanols is extended,
the numbers of hydroxyl groups they offer for H-bonding per
unit volume decreases proportionally. These hydroxyl groups
interact with the polar, H-bonding centers of thalidomide and
its N-alkyl analogs. One can read into this pattern of behavior
that the intermolecular interactions of these collective sol-
vents with the highly polar keto and imido functionalities of
the thalidomide molecule is most determinative of solution
phase activities. Sloan and co-workers (19) determined the
solubility of theophylline in a series of n-alcohols and the
trend in the solubilities was an odd-higher, even-lower molar
solubility pattern up to the C5 alcohol, then a drop in solu-
bility for the C7–C11 alcohols. This sort of odd-higher, even-
lower trend in solubilities was also previously reported for the
solubilities of levonorgestrel in C1–C8 straight chain alcohols
(20).
As suggested in the introduction, there are two simplifi-
cations of Eq. 1 (15) that have been offered by previous in-












Thalidomide 52.1 ± 1.49 61.4 ± 2.03 0.1 ± 0 3.09 ± 1.03
N-Methyl thalidomide 275.9 ± 6.39 370.4 ± 4.27 90 ± 0 14.1 ± 1.05
N-Propyl thalidomide 57.3 ± 1.46 59.4 ± 1.63 220 ± 10 129 ± 1.05
N-Pentyl thalidomide 6.54 ± 0.52 9.0 ± 0.21 530 ± 10 1023 ± 1.06
Table IV. Solubilities of Thalidomide and Analogs in Normal
Alkanols
n-Alkanol









Methanol 4.38 50.66 62.60 129.88
Ethanol 1.55 25.40 44.00 90.34
n-Propanol 1.01 21.25 35.17 81.25
n-Butanol 0.74 16.43 34.50 79.60
n-Pentanol 0.62 14.63 28.53 73.41
n-Hexanol 0.47 11.99 24.20 66.40
n-Heptanol 0.35 10.77 21.50 62.01
n-Octanol 0.27 9.71 20.70 61.55
n-Nonanol 0.23 8.86 19.43 48.38
n-Decanol 0.19 8.75 12.90 38.20
n-Undecanol 0.16 8.42 12.43 35.58
n-Dodecanol 0.16 4.38 10.60 35.24
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vestigators. Neau and Flynn (21) evaluated the merits of the
assumptions regarding Cp. They found that, for compounds
that are rigid such as benzene and polycyclic aromatic hydro-
carbons, Cp is indeed closer to zero than to the entropy of
fusion. However, for compounds that are not rigid, such as
n-alkyl para-aminobenzoates, the value of Cp is better ap-
proximated by the entropy of fusion. The thalidomide mol-
ecule contains a flat phthalimide moiety and an almost
equally flat glutarimide moiety. The latter is not constrained
within a plane but must rotate to a certain extent about its
connection to the phthaloyl portion of the molecule so that
the two portions are not coplanar. Therefore, thalidomide
and its N-alkyl analogs do not appear to be as rigid as the
polycyclic aromatic hydrocarbons but are clearly somewhat
more geometrically constrained than the alkyl-para-amino-
benzoates. It is therefore hard to place them into the best
category represented by these two choices. The influences of
heat capacity assumptions on the estimation of solubility pa-
rameters and ideal solubility were specifically studied by
Neau and co-workers (22). In this study the estimates were
found to be essentially insensitive to the chosen Cp assump-
tion (Cp  0 or Cp  Sf) under the circumstances that
87°C was the largest difference between the melting point and
the solution temperature. However, based on the physico-
chemic properties of hydrocortisone and its solubilities in
London solvents reported by Hagen (23), Neau and co-
workers (22) notes that the heat capacity assumption might
play a significant role in the evaluation of the ideal solubility
under circumstances where the difference between the melt-
ing point and the solution temperature is large. The influence
of these two assumptions on the values of the ideal solubility
and solubility parameters of thalidomide and its N-alkyl ana-
logs, can be seen in Table I. Thalidomide has an extremely
high melting point (275°C), and its solubility parameter is
clearly sensitive to the heat capacity assumption. However, as
anticipated based on previous work reported (21), the heat
capacity assumption had far less effect on the values of the
solubility parameters of the three N-alkyl analog as they all
exhibit melting points 159°C. As can be seen in Table I, the
assumption, Cp equals zero, leads to a value of ln X2,ideal for
thalidomide of −6.65. The alternate assumption, Cp  Sf,
gives a value of ln X2,ideal of −4.82. Thus, on a mol fraction
basis, the ideal solubility of thalidomide differs by a factor of
about six based on the assumption used. However, the mol
fraction ideal solubility of the N-methyl and N-propyl analogs
were only 1.5 times higher when Cp was taken to be equal to
the entropy of fusion. The factor was only 1.3 for the N-pentyl
analog. Thus, the estimated ideal solubility is influenced by
the Cp assumption more profoundly as the difference in
melting and experimental temperature increases. Since tha-
lidomide and its N-alkyl analogs are not fully rigid molecules,
Cp would seem to be better approximated by the entropy of
fusion than by a value of zero in these cases. We have adopted
this approach in further analysis.
Regular solution theory predicts a parabolic relationship
between the mol fraction solubility of a solute and the solu-
bility parameters of “regular” (essentially nonpolar) solvents.
As anticipated, the solubilities of the compounds in London
solvents, closely fit to the respective curves. Figure 2 (A–D)
also demonstrates that regular solution theory is totally inap-
propriate for solubility estimation in solvents like water that
are capable of extensive hydrogen bonding and/or other
strong, orienting bonding with the solute. Specifically, the mol
fraction water solubilities of thalidomide and its N-alkyl ana-
logs are greatly displaced from the regular solution scale. Fig-
ure 2 (A–D) also reflects the differences in solubility param-
eters, as well as the ideal solubility of the compounds, when
Fig. 2. Regular solution parabola for (A) thalidomide, (B) N-methyl
thalidomide, (C) N-propyl thalidomide, and (D) N-pentyl thalido-
mide. (—— Cp  Sp and ------ Cp  0) (  London solvents;
  water).













n-Hexane 7.27 −16.80 −10.05 −9.25 −8.46
Cyclohexane 8.19 −16.25 −9.44 −8.31 −7.25
Carbon tetrachloride 8.55 −12.60 −6.34 −4.75 −2.98
Toluene 8.93 −10.02 −4.58 −3.72 −2.47
Benzene 9.16 −9.68 −4.40 −3.17 −2.13
Water (pH 6.4) 23.0 −12.53 −10.91 −12.58 −14.84
a See Hoy (16).
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using one or the other of the Cp simplifying assumptions. It
is graphically clear that the heat capacity assumption does
have an appreciable impact on the estimations of solubility
parameters and ideal solubilities.
In conclusion, one can clearly see that alkylation of the
thalidomide molecule results in less crystalline compounds of
increased lipophilicity—physicochemical properties that ap-
pear to make them better suited for percutaneous delivery.
When using the equation given by Potts and Guy (24), the
permeability coefficients of thalidomide and its N-alkyl ana-
logs can be estimated from Koct and mw, and based on those
estimates it is expected that the N-alkyl analogs of thalido-
mide will be more easily delivered through the skin than tha-
lidomide itself. In continuing investigations we will determine
the extent to which these basic expectations are actually met.
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